ArticleBiochemistry and biophysics reports2025
Identifying Hub Genes and Pathways in Pancreatic Ductal Adenocarcinoma (PAAD): A comprehensive in silico study.
Article in Biochemistry and biophysics reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One of the most aggressive tumors is pancreatic ductal adenocarcinoma (PAAD), which is usually discovered at an advanced stage and is linked to a poor response to current treatment options and a significant risk of metastasis. Methods: The Gene Expression Omnibus (GEO) database selected GSE15471, GSE28735, GSE62165, and GSE16515. Differentially expressed genes (DEGs) were defined as having a logFC of >1 and ≤ -1 and an adjusted p-value of less than 0.05. Differentially expressed genes (DEGs) from the four datasets were identified using the GEO2R tool. KEGG and GO databases were used to identify related pathways. PPIs were analyzed using Cytoscape and Gephi. A GEPIA analysis confirmed the target genes. Results: The analysis of protein-protein interactions (PPI) along with data from the Gene Expression Omnibus (GEO) led to the identification of 66 hub genes and 819 common differentially expressed genes (DEGs). GO and KEGG pathway analyses indicated that these DEGs are significantly associated with functions related to cell adhesion, extracellular exosomes, structural components of the extracellular matrix, and the cytoskeleton in muscle cells. The expression levels of 8 genes-FN1, CXCR4, MMP9, PXDN, CBS, ALB, GPT2, and EGF-demonstrated a notable difference between normal and tumor samples, as identified through GEPIA analysis. Conclusion: The hub genes and related pathways that are connected to the development of PAAD were found in this study. These genes could serve as promising diagnostic biomarkers, offering a valuable chance to detect PAAD in its initial stages, leading to more effective treatment options.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.